Compare Meta Platforms Inc (META) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Meta Platforms Inc trades at $718.26 (market cap $1.84T), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Meta Platforms Inc is far larger — about 14.4× Vertex Pharmaceuticals Incorporated's market cap, and Meta Platforms Inc pays a 0.29% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| META | VRTX | |
|---|---|---|
Market Cap | $1.84T | $127.55B |
Volume | 15,887,049 | 1,487,944 |
Sector | Media | Health |
52-Week High | $777.59 | $557.96 |
52-Week Low | $525.72 | $407.37 |
Typical Hold Time | 127 Days | 120 Days |
Enterprise Value | $1.86T | $121.68B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $718.67, down 0.37% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $201B in 2025 and maintains robust profitability with 29.84% net margins. Recent AI developments, including the Muse Spark launch, and a $21B deal with CoreWeave highlight strategic positioning. Analyst consensus is strongly bullish with an 80% buy rating and $781 price target, though legal challenges and high capital expenditures present headwinds.
META's outlook remains positive driven by AI innovation and solid fundamentals, but investors face risks from regulatory lawsuits and volatile tech sentiment. The stock offers upside to consensus targets if execution continues, yet high valuation multiples and market rotation pressures warrant caution. Balancing growth prospects with legal and competitive risks is key for medium-term performance.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
